期刊文献+

川南地区乳腺癌患者HER-2基因状态及其蛋白表达与临床病理特征的关系分析 被引量:10

下载PDF
导出
摘要 目的探讨乳腺癌组织中人表皮生长因子受体-2(HER-2)基因状态与HER-2/neu蛋白表达的一致性、相关性及其与临床病理特征的关系。方法采用荧光原位杂交(FISH)及免疫组织化学(IHC)法检测898例乳腺癌组织HER-2基因扩增与蛋白表达,对二者结果的一致性、相关性及其与临床病理特征的关系进行评价。结果FISH与IHC检测符合率如下:IHC(-/+)为93.79%,IHC(++)为7.17%,IHC(+++)为60.98%。二者检测结果存在一致性(Kappa=0.132,P=0.000),且呈正相关(r=0.351,P<0.01)。雌激素受体(ER)表达与HER-2基因扩增及蛋白表达呈负相关(r=-0.322,P<0.01;r=-0.114,P<0.01),孕激素(PR)表达及ER/PR状态与HER-2基因扩增呈负相关(r=-0.177,P<0.01;r=-0.234,P<0.01),与HER-2蛋白表达无关(P>0.05)。另外,年龄、淋巴结转移状态与HER-2基因扩增状态相关,肿瘤大小和组织学分级与HER-2蛋白表达有关。结论IHC(-/+)者与FISH结果高度一致性,IHC(++)、IHC(+++)者,FISH检测仍然是评价HER-2基因扩增的标准方法。
出处 《重庆医学》 CAS 2019年第11期1937-1940,共4页 Chongqing medicine
基金 四川省卫生厅项目(120364) 西南医科大学博士启动基金项目(2011204) 西南医大-泸州市科知局联合课题(2017LZXNYDJ14)
  • 相关文献

参考文献7

二级参考文献91

  • 1张瑰红,施达仁,梁晓曼,侯景辉,康苏娅,朱卫东,李晓兵,邵云,陈丽荣,周燕.显色原位杂交和免疫组织化学检测乳腺癌HER2/neu基因状况和蛋白表达的对照性研究[J].中华病理学杂志,2006,35(10):580-583. 被引量:29
  • 2<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 3Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol, 2007, 25 : 118-145. 被引量:1
  • 4Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science, 1987, 235 : 177-182. 被引量:1
  • 5Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Eng J Med, 2001, 344:783- 792. 被引量:1
  • 6Marty M, Cognetti F, Maraninehi D, et al. Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol, 2005, 23: 4265 -4274. 被引量:1
  • 7Papaldo P, Fabi A, Ferretti G, et al. A phase Ⅱ study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Ann Oncol, 2006, 17: 630-636. 被引量:1
  • 8Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase Ⅲ TANDEM study. J Clin Oncol, 2009, 27:5529-5537. 被引量:1
  • 9von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol, 2009, 27: 1999- 2006. 被引量:1
  • 10Cameron D, Casey M, Press M, et al. A phase Ⅲ randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat, 2008, 112:533-543. 被引量:1

共引文献422

同被引文献89

引证文献10

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部